News

Maze Therapeutics Begins Groundbreaking Phase 2 Study for Kidney Disease

Maze Therapeutics Begins Groundbreaking Phase 2 Study for Kidney Disease

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Trial

Maze Therapeutics, Inc. (Nasdaq: MAZE) has announced an important milestone in its clinical research efforts. The company has dosed the first patient in the Phase 2 clinical trial known as the HORIZON Study, which evaluates MZE829 as a potential treatment for patients suffering from APOL1 kidney disease (AKD). This innovative oral small molecule inhibitor is designed specifically to target the genetic underpinnings associated with AKD, a serious condition estimated to afflict over one million individuals in the United States.

What Is the HORIZON Study?

The HORIZON Study is a Phase 2, open-label trial featuring a basket design aimed at assessing the effectiveness of MZE829. In this study, participants with AKD who carry the high-risk APOL1 alleles (G1, G2) will be stratified based on their clinical characteristics and level of proteinuria. This differentiation allows for a nuanced understanding of MZE829’s therapeutic impact across various patient profiles, including those with related conditions such as type 2 diabetes.

The Importance of Patient Diversity

One of the distinguishing features of the HORIZON Study is its inclusive enrollment criteria, which seek to capture a wide diversity of patients. From those experiencing severe symptoms like nephrotic range proteinuria to individuals with milder manifestations, the trial represents a comprehensive approach to tackling AKD. Furthermore, it is the first of its kind to investigate the impact of a small molecule APOL1 inhibitor on diabetic patients suffering from AKD, highlighting Maze’s commitment to innovative research.

Endpoints and Evaluation Metrics

The primary goal of the HORIZON Study is to measure the reduction of proteinuria, a marker of kidney function. Specifically, researchers aim to identify the percentage of trial participants who experience a 30% or greater decrease in their urinary albumin-to-creatinine ratio (uACR) by week 12. Existing literature supports the use of uACR as a significant indicator of clinical benefit, especially in the context of hypertension and diabetes.

Looking Forward

The excitement surrounding the HORIZON Study is palpable, with Maze expecting to present proof of concept interim data as early as the first quarter of 2026. The potential implications for patients suffering from AKD are monumental, as MZE829 may usher in a new era of treatment aimed at fundamentally altering the course of this disease.

About Maze Therapeutics

Maze Therapeutics stands out in the biopharmaceutical landscape as a clinical-stage company dedicated to leveraging human genetics in the development of small molecule precision medicines. The company’s focus prioritizes renal, cardiovascular, and metabolic diseases, addressing critical health challenges that face many individuals today. The innovative Compass platform utilized by Maze provides valuable insights into the genetic factors that drive disease progression, guiding the development of personalized treatment options.

Pipeline and Future Developments

The company's pipeline features two key programs, MZE829 and MZE782, both representing groundbreaking approaches tailored to the unique needs of patients. As Maze Therapeutics continues to advance its research agenda, the potential for impactful treatments expands. MZE829's unique properties position it as a promising agent in the fight against kidney disease, packed with the potential to improve patient outcomes.

Frequently Asked Questions

What is MZE829?

MZE829 is an oral small molecule APOL1 inhibitor being evaluated by Maze Therapeutics for its efficacy in treating APOL1 kidney disease.

What are the key goals of the HORIZON Study?

The primary objective is to reduce proteinuria significantly, aiming for a 30% or greater drop in urinary albumin-to-creatinine ratio in participants over 12 weeks.

Who is eligible for the HORIZON Study?

Patients with APOL1 kidney disease carrying the high-risk G1 and G2 alleles, as well as those with type 2 diabetes, may participate in the study.

When is the expected data readout for the trial?

Maze Therapeutics anticipates releasing proof of concept interim data in the first quarter of 2026.

What other conditions is Maze Therapeutics focusing on?

In addition to AKD, Maze Therapeutics is developing treatments aimed at cardiovascular and related metabolic diseases, using insights from genetics.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 255

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 69

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 136

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 131

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 148

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
Fold Health's AI: Revolutionizing Patient Care Dynamics

Updated Category News Views 140

AI's Role in Healthcare: From Insight to Action Healthcare's got a resource issue, plain and simple. It's like trying to fill a bathtub with a hole in it—clinicians are swamped, burnout is high, and patients aren't getting the attention they need. Enter Fold Health's AI operating layer, launched with the ambition to realign the equation. Not Just Another Tech Buzzword...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 63

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Monotype Unveils Font Tool for Adobe: A Game-Changer?

Updated Category News Views 165

Monotype Connect: Fonts Meet Convenience Imagine fighting through a blizzard with a flashlight. That's how designers juggle fonts without a central tool. Well, Monotype's got them covered with the new Connect panel for Adobe apps—a beacon of efficiency spotted at Adobe MAX 2026 in Miami Beach. Efficiency and Brand Unity: Partners in Design Now, here’s why this isn’t...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 120

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Insights from OncoHost in Lung Cancer Treatment Strategy

Updated Category News Views 149

New Advances in Understanding Lung Cancer Treatment Resistance Recent findings from OncoHost shed light on the mechanisms behind resistance to immunotherapy in patients battling lung cancer. The study presents vital insights aimed at improving therapeutic strategies through advanced plasma proteomics analysis. Insights from Advanced Plasma Proteomics OncoHost, a...

Continue Reading
Understanding Eldorado Gold's Current Market Position and P/E

Updated Category News Views 167

Analyzing Eldorado Gold Inc's Current Market Situation At present, Eldorado Gold Inc. (NYSE: EGO) shares trade at a price of $27.34, reflecting a decrease of 5.85% in the current session. This decline comes after a slight drop of 1.19% over the past month. Despite this short-term volatility, when looking over a longer timeline, the stock shows impressive growth, having...

Continue Reading
Truecaller Achieves Remarkable Growth with 450 Million Users

Updated Category News Views 218

Truecaller Reaches 450 Million Monthly Active Users Truecaller, the renowned platform dedicated to verifying contacts and blocking unwanted communications, has reached a significant milestone, surpassing 450 million active users. This achievement marks another step in its impressive growth trajectory over the last year, with around 50 million new users added in just ten...

Continue Reading
Shell plc's Recent Share Buybacks: Key Insights Revealed

Updated Category News Views 377

Overview of Shell plc's Share Buyback Activities Shell plc has recently initiated significant share buyback activities as part of its ongoing strategy to enhance shareholder value. This move demonstrates the company's commitment to investing back into itself and optimizing capital allocation. The buybacks reflect Shell's strong financial position and positive outlook on...

Continue Reading
Wyndham Hotels Investigation: Uncovering Potential $50 Million Loss

Updated Category News Views 324

Investigation into Wyndham Hotels Sparks Concern Recent findings from internal records of Wyndham Hotels & Resorts have revealed alarming information suggesting that the Royalton Letter of Credit (LOC) was fully funded but not released. This situation raises troubling questions about potential securities and franchise-law violations involving multiple parties....

Continue Reading